KeyOptions News & Blog

As we continue to extend our reach across the Globe, we are about to announce an exciting update f...

21/07/2021
Read more

KeyOptions announces its release of ‘HealthKeyID’

16/07/2021
Read more
Icon-512.png

HealthKeyID finally on Google Play

14/07/2021
Read more

HealthKeyID IS now available on the Samsung Galaxy Store

07/07/2021
Read more

Hartlepool college helping electronics firm recruit for 100 new jobs for ultra-fast Covid-19 test

02/07/2021
Read more
image (50).png

  As Covid-19 shows no sign of decline, KeyOptions continues to focus its efforts in working with...

02/07/2021
Read more
image (46).png

Locationing Analytics & Monitoring

02/07/2021
Read more

Getting the world moving again

Virolens®

Please note that Virolens may not be available in all countries due to local regulatory authority approvals.

Certifications are currently underway in most geographies and are being managed by our local distributor network.

The Science

Identifying and screening COVID-19 patients quickly and effectively is key to getting the world moving again.  Virolens is a rapid screening system that can be used at almost any location - airports, sporting events, schools, theatres, retail and offices.

Virolens allows people to get on with their everyday lives safe in the knowledge they are in a COVID-free environment.

Technology matters

The Virolens system is a screening device that combines holographic microscopy with artificial intelligence (AI) to detect SARS-CoV-2, the virus that causes COVID-19 disease. Virolens is constructed to the highest standards, designed and manufactured in the UK.

STEP 1

The Virolens® system uses a  mouth swab, which is placed inside a cartridge and inserted into the system. The Virolens system is a portable floor-standing device.

Step 2

Inside the Virolens® system is a holographic microscope designed to look at nano-scale structures. Light is projected onto the slide creating identifiable diffraction patterns.

Step 3

The holographic image data is analysed using AI to identify the unique pattern of the virus from other cells very quickly.

Step 4

The Virolens® system is completely self-contained and can give a yes/no result in around 20 seconds with the whole process taking about 1 minute.

Advantages

A new application of existing technologies

This is a brand-new screening device which combines microscopic holographic imaging and artificial intelligence (AI) software technology.

Quick and easy

The system does not require a trained biologist to determine the results. It takes around 20 seconds to get a yes/no result.

Accurate

Virolens has a 97.3% sensitivity and 99.7% specificity.

Safe

The samples from the screening process are collected and sanitised prior to recycling.

Able to collect anonymised data

The system collects anonymised data which can be interrogated to understand the spread of SARS-Cov-2. (COVID-19) in screening areas.

Future proof software

The system can detect virus patterns as they evolve and change, meaning it will remain effective. Providing the emerging variants of the virus maintain the macro structure of the SARS-Cov-2 pathogen including the external protein signature, the Virolens system will continue to detect the virus. The AI technology deployed in the Virolens system can be trained to detect virus patterns as they evolve and change, including the detection of other diseases. iAbra maintains close monitoring of SARS-CoV-2 variants. 

Applicable to other diseases

Currently the system is only trained to look for and recognise COVID-19 but iAbra is working to extend it to other diseases by using the same AI technology.

Affordable

Tests will be low cost compared to existing testing solutions.

The virolens collaboration

Background

About IAbra

Founded in 2010, iAbra's focus is deriving utility from the ever-growing amounts of sensor data in the world.

Artificial Intelligence is moving from the cloud to embedded applications.This is enabling a wide range of use cases including automotive, defence, manufacturing, healthcare and agriculture.

Machine Learning ecosystems have been built mostly on GPUs for the cloud, where neural networks are generally very large and inefficient. These cloud-based neural networks and power-hungry GPUs make the AI use cases requiring embedded inference more difficult or impossible to engineer. The FPGA's efficiency and low power consumption are better able to deliver embedded applications.

iAbra's tools ensure that efficient neural networks are created and optimised for embedded FPGA silicon, delivering low power AI inference for a variety of applications.

About TT Electronics

TT Electronics is a global provider of engineered electronics for performance critical applications. With around 5,000 employees operating from 30 key locations around the world, TT designs and manufactures a wide range of electronics for sensing, power management and connectivity primarily for applications in the industrial, medical and aerospace and defence sectors.


www.ttelectronics.com

KeyOptions & Virolens

KeyOptions is the iAbra appointed Master agent for Virolens In Asia Pacific, Latin America Turkey & Eurasia and parts of Africa. Whilst KeyOptions is bringing the Virolens solution to market, our core focus is to provide some of our more traditional services around the Virolens solution. Over the coming months we will be announcing:

  • Consulting services
  • Systems integration into existing environments
  • HealthKeyID to manage Virolens and other testing
  • Our Assets-in-Motion solution to better manage Virolens machines, accessories, and other data analytics.
  • Customised App development for clients specific needs
  • Managed services
  • We see a whole new eco-system being built around the Virolens system on the successful introduction of the system

Please contact us at virolens@keyoptions.com if you would like any further information on using Virolens in your environment.

Please note that Virolens may not be available, or be able to be advertised in all countries due to local regulatory authority approvals.

Certifications are currently underway in most geographies and are being managed by our distributor network.

Currently, Virolens is not approved for advertising or for sale in Australia

Please contact virolens@keyoptionsgroup.co.uk for country availability

We use cookies
Cookie preferences
Below you may find information about the purposes for which we and our partners use cookies and process data. You can exercise your preferences for processing, and/or see details on our partners' websites.
Analytical cookies Disable all
Functional cookies
Other cookies
We use cookies to personalize content , to provide social media features and to analyze our traffic. Learn more about our cookie policy.
Change preferences Accept all
Cookies